New Opportunities via Novel Formulation Technologies
Ascendia Pharmaceuticals CEO, Jim Huang, describes how new opportunities in formulation development complement the company’s previous work in developing novel nanotechnologies to support biopharmaceutical development.
Jim Huang, CEO of Ascendia Pharmaceuticals discusses:
- Ascendia Pharmaceuticals growth and culture
- Recent advances including the company's fourth nanotechnology – LipidSol
Related Content
